Document:

EX-10.2

 

Exhibit 10.2

Brian J. G. Pereira, M.D. Joins Biodel’s Board of Directors

DANBURY, Conn., November 21, 2007 —Biodel, Inc. (Nasdaq: BIOD) today announced the addition of
Brian J.G. Pereira, M.D., to its Board of Directors.

Dr. Pereira is the President and CEO of AMAG Pharmaceuticals, Inc., a biopharmaceutical company
dedicated to the development and commercialization of therapeutic and diagnostic products. At
AMAG Pharmaceuticals, Dr. Pereira played an integral role in advancing the company’s key product
candidate, Ferumoxytol, towards marketing approval with the U.S. Food and Drug Administration.

“Brian brings an incredible wealth of knowledge to Biodel from his years of experience in the
biotechnology and medical community,” said Dr. Solomon Steiner, CEO and Chairman of Biodel. “As we
grow our company and advance our clinical products, Brian’s insights and perspectives will be
invaluable. We are excited and honored he has chosen to serve on Biodel’s Board of Directors.”

“Sol and his team have done an excellent job in advancing the clinical development of their lead
product candidate, VIAjectTM,” said Dr. Pereira. “I have been particularly impressed with the
company’s commitment to developing novel insulin treatments for the diabetes population. I look
forward to working with Biodel’s great board members who have guided this Company’s development.”

Prior to joining AMAG Pharmaceuticals, Dr. Pereira served as President and CEO of New England
Health Care Foundation, an independent 501(c)(3) corporation that employs staff physicians at
Tufts-New England Medical Center. Dr. Pereira has also held various other positions at Tufts-New
England Medical Center, including Interim Chief Operating Officer, Senior Vice President and
Executive Director, Vice Chairman for Strategic Development in the Department of Medicine and Staff
physician in the Division of Nephrology.

Dr. Pereira is a nationally recognized expert on kidney disease and has served on the editorial
board of twelve scientific journals. He is the editor of the widely read textbook, “Chronic Kidney
Disease, Dialysis and Transplantation,” and has over 200 scientific papers to his credit. Dr.
Pereira is Chairman of the Board of the Harvard-MIT Biomedical Enterprise Program, a member of the
Board of Directors of Satellite Health Care and the National Kidney Foundation, and an advisor to
several other organizations. Dr. Pereira is a graduate of both St. John’s Medical College and Post
Graduate Institute of Medical Education and Research in India. He received his M.B.A. from Kellogg
Graduate School of Management at Northwestern University.

 

 

Exhibit 10.2

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and
commercialization of innovative treatments for endocrine disorders, such as diabetes and
osteoporosis. Biodel’s product candidates are developed by using VIAdelTM technology, which
reformulates existing FDA-approved peptide drugs. The Company’s lead product candidate, VIAjectTM,
is a rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or
Type 2 diabetes. VIAjectTM is currently being tested in two pivotal Phase III clinical trials.
Biodel’s pipeline also includes VIAtabTM, a sublingual tablet formulation of insulin in Phase I
clinical trials and two osteoporosis product candidates in pre-clinical studies. For further
information regarding Biodel, please visit the Company’s website at http://www.biodel.com.

Safe Harbor

This press release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements, other then statements of historical facts,
including statements regarding our strategy, future operations, future financial position, future
revenues, projected costs, prospects, plans and objectives of management are forward-looking
statements. The words “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,”
“may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” and similar
expressions are intended to identify forward-looking statements, although not all forward-looking
statements contain these identifying words. The Company’s forward-looking statements are subject
to a number of known and unknown risks and uncertainties that could cause actual results,
performance or achievements to differ materially from those described or implied in the
forward-looking statements, including, but not limited to, our ability to secure FDA approval for
our product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; our
ability to market, commercialize and achieve market acceptance for product candidates developed
using our VIAdelTM technology; the progress or success of our research, development and clinical
programs, the initiation and completion of our clinical trials, the timing of the interim analyses
and the timing or success of our product candidates, particularly VIAjectTM and VIAtabTM; our ability
to secure additional patents for VIAjectTM and our other product candidates; our ability to protect
our intellectual property and operate our business without infringing upon the intellectual
property rights of others; our estimates of future performance; our ability to enter into
collaboration arrangements for the commercialization of our product candidates and the success or
failure of those collaborations after consummation, if consummated; the rate and degree of market
acceptance and clinical utility of our products; our commercialization, marketing and manufacturing
capabilities and strategy; our estimates regarding anticipated operating losses, future revenues,
capital requirements and our needs for additional financing; and other factors identified in our
Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. The Company disclaims any
obligation to update any forward-looking statements as a result of events occurring after the date
of this press release.

 

 

Exhibit 10.2

BIOD-G

Contact:

Investors, should contact Clay A. Kramer, ckramer@burnsmc.com, or Media, Carney Noensie,
cnoensie@burnsmc.com, both of Burns McClellan, Inc., +1-212-213-0006, for Biodel Inc.

###EX-4.1

 

Exhibit 4.1

SUPPLEMENTAL INDENTURE NO. 1

     This SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”) is dated as of
November 16, 2007, among Legacy Vulcan Corp. (formerly known as “Vulcan Materials
Company”), a New Jersey corporation (the “Company”), Vulcan Materials Company (formerly
known as “Virginia Holdco, Inc.”), a New Jersey corporation (“Holdco”), and The
Bank of New York Trust Company, N.A., as successor trustee (together with its successors in trust,
the “Trustee”) under the Indenture (as hereinafter defined).

     WHEREAS, the Company and the Trustee (as successor to Morgan Guaranty Trust Company of New
York and The Bank of New York) are parties to an Indenture, dated as of May 1, 1991 (the
“Indenture”), pursuant to which the Company issued its $250 million 6.00% Notes due 2009
(the “2009 Notes”) and $5 million 8.8% medium-term notes due 2011, $10 million 8.7%
medium-term notes due 2013, and $6 million 8.85% medium term notes due 2021 (the “Medium-Term
Notes”, and together with the 2009 Notes, the “Securities”);

     WHEREAS, on February 19, 2007, the Company entered into an Agreement and Plan of Merger, as
amended (the “Merger Agreement”) with Holdco, Florida Rock Industries, Inc. (“Florida
Rock”), Virginia Merger Sub, Inc. (“Virginia Merger Sub”), and Fresno Merger Sub, Inc.
(“Fresno Merger Sub”), pursuant to which (i) Virginia Merger Sub will merge with and into
the Company, with the Company being the surviving company and a wholly owned subsidiary of Holdco
and (ii) Fresno Merger Sub will merge with and into Florida Rock, with Florida Rock being the
surviving company and a wholly owned subsidiary of Holdco (the “Mergers”);

     WHEREAS, in connection with the Mergers, Holdco desires to fully and unconditionally guarantee
to each Holder the full and punctual payment of the principal of, premium, if any, and interest on
the Securities on the dates and in the manner provided for in the Indenture and the Securities;

     WHEREAS, Section 901(5) of the Indenture provides that, without the consent of any Holders,
the Company, when authorized by a Board Resolution, and the Trustee, at any time and from time to
time, may enter into one or more supplemental indentures, to add to, change or eliminate any of the
provisions of the Indenture in respect of one or more series of Securities, provided that any such
addition, change or elimination shall not modify the rights of the Holder of any such Security with
respect to such provision;

     WHEREAS, the execution and delivery of this instrument have been duly authorized and all
conditions and requirements necessary to make this instrument a valid and binding agreement have
been duly performed and complied with; and

     WHEREAS, this Supplemental Indenture is being executed immediately after the closing of the
Mergers;

     NOW, THEREFORE, in consideration of the premises set forth herein and for other good and
valuable consideration, the receipt and sufficiency of which are hereby

 

 

acknowledged, it is mutually covenanted and agreed, for the equal and proportionate benefit of
all Holders, as follows:

ARTICLE 1.   HOLDCO GUARANTEE

     Section 1.01.   Holdco hereby fully and unconditionally guarantees to each Holder the full and
punctual payment when due, whether at Stated Maturity, by acceleration, by redemption or otherwise,
of all obligations of the Company under the Indenture and the Securities, whether for payment of
principal of, premium, if any, or interest on the Securities and all other monetary obligations of
the Company under the Indenture and the Securities. Holdco hereby waives diligence, presentment,
demand of payment, any right to require a proceeding first against the Company, protest or notice
and all demands whatsoever with respect to the Securities or the indebtedness evidenced thereby.

     Section 1.02   The agreements of Holdco herein shall be valid and obligatory with respect to any
Security that heretofore or hereinafter has been authenticated and delivered under the Indenture.

ARTICLE 2.   MISCELLANEOUS

     Section 2.01.   On the date hereof, the Indenture shall be supplemented and amended in
accordance herewith, and this Supplemental Indenture shall form part of the Indenture for all
purposes, and the Holder of every Security heretofore or hereafter authenticated and delivered
under the Indenture shall be bound thereby. The Trustee accepts the trusts created by the
Indenture, as amended and supplemented by this Supplemental Indenture, and agrees to perform the
same upon the terms and conditions of the Indenture, as amended and supplemented by this
Supplemental Indenture.

     Section 2.02.   Capitalized terms used herein and not defined herein have the meanings ascribed
to such terms in the Indenture.

     Section 2.03.   This Supplemental Indenture shall become effective as of the date hereof at such
time as executed counterparts of this Supplemental Indenture have been delivered by each party
hereto to the other party thereto.

     Section 2.04.   All provisions of this Supplemental Indenture shall be deemed to be incorporated
in, and made a part of, the Indenture. The Indenture, as amended and supplemented by this
Supplemental Indenture, shall be read, taken and construed as one and the same instrument and all
provisions in the Indenture and the Securities shall remain in full force and effect.

     Section 2.05.   In case any one or more of the provisions contained in this Supplemental
Indenture shall for any reason be held to be invalid, illegal or unenforceable in any respect, such
invalidity, illegality or unenforceability shall not affect any other provisions of this
Supplemental Indenture, but this Supplemental Indenture shall be construed as if such invalid,
illegal or unenforceable provision had never been contained herein.

2

 

     Section 2.06.  The parties may sign any number of copies of this Supplemental Indenture. Each
signed copy shall be an original, but all of them together represent the same agreement. One signed
copy is enough to prove this Supplemental Indenture.

     Section 2.07.  The Trustee shall not be responsible in any manner whatsoever for or in respect
of the validity and sufficiency of this Supplemental Indenture or for or in respect of the recitals
contained herein, all of which are made solely by the Company and Holdco.

     Section 2.08.  In entering into this Supplemental Indenture, the Trustee shall be entitled to
the benefit of every provision of the Indenture and the Securities relating to the conduct or
affecting the liability of or affording protection to the Trustee, whether or not elsewhere herein
so provided.

     Section 2.09.  All covenants and agreements in this Supplemental Indenture by the Company and
the Trustee shall bind their respective successors and assigns. Nothing in this Supplemental
Indenture, express or implied, shall give to any person, other than the parties hereto and their
successors under the Indenture and the Holders of the Securities, any benefit of any legal or
equitable right, remedy or claim under the Indenture.

     Section 2.10.  This Supplemental Indenture shall be governed by, and construed in accordance
with, the laws of the State of New York.

[Signature page follows]

3

 

     IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed as of the day and year first above written.

	 	 	 	 	 
	 	LEGACY VULCAN CORP.

 	 
	 	By:  	 /s/
Daniel F. Sansone	 
	 	 	Name:  	 Daniel F. Sansone	 
	 	 	Title:  	 Senior Vice President and

Chief Financial
Officer	 
	 
	 	VULCAN MATERIALS COMPANY

 	 
	 	By:  	 /s/
Daniel F. Sansone	 
	 	 	Name:  	 Daniel F. Sansone	 
	 	 	Title:  	 Senior Vice President and

Chief Financial
Officer	 
	 
	 	THE BANK OF NEW YORK TRUST COMPANY, N.A.,

Trustee

 	 
	 	By:  	 /s/
Charles S. Northen, IV	 
	 	 	Name:  	 Charles S. Northen, IV	 
	 	 	Title:  	 Vice President	 
	 

[Supplemental Indenture Signature Page]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}]]